Place in the Classification of Hypolipidemic Agents
In pharmacological classification, gemfibrozil is a fibric acid derivative. For a comprehensive medical understanding, remember that in addition to fibrates, other major drug classes include HMG-CoA reductase inhibitors (statins), cholesterol absorption inhibitors (e.g., ezetimibe), bile acid sequestrants (cholestyramine), and nicotinic acid derivatives. While statins primarily block cholesterol synthesis, fibrates have a different primary site of action and clinical profile.
Mechanism of Action
The mechanism of gemfibrozil acts at the genetic level. The drug functions as an agonist for PPARα (peroxisome proliferator-activated receptor alpha). By binding to this target, the drug triggers a cascade of biochemical reactions:
- Stimulates the expression of endothelial lipoprotein lipase.
- Increases the synthesis of Apo A protein, which is the main structural component of high-density lipoproteins (HDL).
- Suppresses hepatic cholesterol synthesis (presumably via inhibition of HMG-CoA reductase) and reduces the production of very-low-density lipoproteins (VLDL).
- Increases the density of lipoprotein receptors on hepatocyte membranes.
Pharmacological Effects
Activation of PPARα receptors leads to a marked alteration in the patient's lipid profile. The key effect is the acceleration of VLDL and intermediate-density lipoprotein (IDL) catabolism, resulting in a profound reduction in triglyceride (TG) levels. Targeting triglycerides is the hallmark of fibrates.
Additional effects include a reduction in 'atherogenic' low-density lipoproteins (LDL) and an increase in 'anti-atherogenic' HDL concentration.
Onset of action: initial effects are observed within 2–5 days of starting therapy, with peak therapeutic effect achieved by the 4th week of regular intake.
Pharmacokinetics
The drug features high bioavailability, with approximately 97% of the active substance absorbed from the gastrointestinal tract upon oral administration. Peak plasma concentrations are reached rapidly within 1 to 2 hours. Gemfibrozil is metabolized in the liver, and its elimination half-life ($t_{1/2}$) is 1.5 hours. Elimination occurs predominantly via the kidneys, with up to 70% of the drug excreted unchanged.
Indications
In clinical practice, gemfibrozil is prescribed for hyperlipoproteinemias (HLP) types II, IV, and V. The drug is a preferred option when there is a clinical necessity to aggressively lower serum triglyceride levels.
Adverse Effects and Contraindications
When prescribing this drug, potential adverse reactions across various organ systems must be considered:
- Musculoskeletal system (critical): development of myalgia, myopathy, and in rare cases, severe rhabdomyolysis.
- Gastrointestinal tract and liver: dyspepsia, risk of cholestasis.
- Central nervous system: headache, transient blurred vision.
Dangerous Drug Interaction: Gemfibrozil is an inhibitor of the hepatic transporter OATP1B1. This transporter is responsible for the hepatic uptake of statins. When co-administered, gemfibrozil blocks this transporter, leading to two major consequences:
- Reduced therapeutic efficacy of statins (they fail to enter the liver where they are supposed to act).
- Sharp increase in systemic toxicity (statins accumulate in the blood and damage muscle tissue).
For this reason, combining gemfibrozil with statins is strictly contraindicated due to the high risk of additive adverse effects and severe myopathy.